Novartis appoints Fiona Marshall as President of Novartis Institutes for Biomedical Research | The Financial Express

Novartis appoints Fiona Marshall as President of Novartis Institutes for Biomedical Research

Prior to joining Merck in 2018, Dr. Marshall was a Founder and Chief Scientific Officer of Heptares Therapeutics.

Novartis appoints Fiona Marshall as President of Novartis Institutes for Biomedical Research
Fiona H. Marshall, Ph.D., currently Senior Vice President and Global Head of Discovery Sciences, Preclinical Development and Translational Medicine at MSD (Merck & Co., Inc in USA), has been appointed as President of the Novartis Institutes for BioMedical Research (NIBR) (Image Credit: Novartis Website)

Novartis on Thursday announced that James (Jay) E. Bradner, M.D., will step down from the Executive Committee of Novartis (ECN), effective October 31st after seven years leading research at Novartis.

According to a press statement on Thursday, Fiona H. Marshall, Ph.D., currently Senior Vice President and Global Head of Discovery Sciences, Preclinical Development and Translational Medicine at MSD (Merck & Co., Inc in USA), has been appointed as President of the Novartis Institutes for BioMedical Research (NIBR), effective November 1st, 2022 reporting to Vas Narasimhan, M.D., CEO of Novartis. Dr. Marshall will become a member of the ECN.

“Leading NIBR has been a privilege for which I will forever be grateful. I am so proud of the medicines we have imagined together, and I am confident that Fiona and our leaders will continue the creative, productive and important research to the definitive benefit of those with life-threatening diseases,” Jay Bradner said in a statement.

Prior to joining Merck in 2018, Dr. Marshall was a Founder and Chief Scientific Officer of Heptares Therapeutics, a UK Biotech company focused on structure-based drug design that was subsequently acquired by the Japanese biotech company Sosei, where she continued to serve as Chief Scientific Officer.

“I am very excited to join Novartis and lead the discovery teams who are renowned for their collaborative research and use of cutting-edge technologies. I look forward to working with them, colleagues across Novartis and our partners across the biopharma ecosystem to accelerate the translation of scientific discoveries into breakthrough medicines that address critical areas of unmet need for patients,” Fiona Marshall said in a statement.

ALSO READ | Novartis announces intention to separate Sandoz business to create standalone company

Get live Share Market updates and latest India News and business news on Financial Express. Download Financial Express App for latest business news.